1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2017

  • February 2017
  • 153 pages
  • Global Markets Direct
Report ID: 2183451

Summary

Table of Contents

Search Inside

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) – Pipeline Review, H1 2017, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape.

Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 8, 7, 12, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Cell Division Protein FtsZ (ftsz) - Pipeline Review, H1 2017

  • $ 3500
  • Company report
  • June 2017
  • by Global Markets Direct

Cell Division Protein FtsZ (ftsz) - Pipeline Review, H1 2017 Summary Cell Division Protein FtsZ (ftsz) - FtsZ is a protein encoded by the ftsZ gene. It is essential cell division protein that forms a contractile ...

Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H1 2017

  • $ 2000
  • Company report
  • April 2017
  • by Global Markets Direct

Resistant Pseudomonas aeruginosa Infections - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Resistant Pseudomonas aeruginosa Infections ...

Schistosomiasis - Pipeline Review, H1 2017

  • $ 2000
  • Company report
  • April 2017
  • by Global Markets Direct

Schistosomiasis - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schistosomiasis – Pipeline Review, H1 2017, provides an overview ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.